PPARG and lung cancer: Most significantly, one epidemiologic analysis of diabetic patients from 10 Veterans Affairs medical centers, comparing 11,289 TZD users with 76,389 nonusers, observed a 33% reduction in subsequent lung cancer diagnosis in the former group [68], thus underscoring the chemopreventive potential of PPARγ agonists.